You are here
GMSI Award 2015 – Role of microglia in the pathogenesis of progressive multiple sclerosis
This lecture was given at the Grant for Multiple Sclerosis Innovation Awards Event, 8th October 2015. The GMSI award was supported by Merck KGaA, Darmstadt, Germany. Dr. Airas is an award winner and works at the University of Turku, Finland.
In her speech, the award winner Dr. Airas, said that it had been very difficult to find treatments for progressive multiple sclerosis. One reason was that the pathology changes as the disease progresses. In progressive MS, the inflammation was contained within the nervous system. Conventional disease modifying treatments were not so helpful in progressive disease, as these mainly worked on the peripheral immune system.
Dr. Airas proposed the following pathological model for progressive multiple sclerosis: There was an initial insult that leads to neurodegeneration. This led to over-representation of the M1 cells and these produced pro-inflammatory cytokines and oxidative stress, which harmed more neurons. This was a vicious circle that perhaps could be stopped by targeting the M1 microglia.
According to Dr. Airas, the first aim of the project was to demonstrate by specific PET imaging that the transition from relapsing remitting multiple sclerosis was related to microglial activation from M1 to M2. The second aim was to find a pharmacological approach to prevent or reverse this, possibly by purinergic receptor activation. These would then repair debris and allow remyelination. Possible compounds would be screened in the EAE animal model.
David Bates11/09/2015 - 10:41Professor Bates said that the GMSI [Grant for Multiple Sclerosis Innovation] was first awarded in 2013. Merck Serono provides research grants of up to 1 million Euros and thereby demonstrated its commitment to immunology...
Steven Hildemann11/09/2015 - 10:49Merck-Serono's pipeline focuses on difficult to treat diseases with a high unmet medical need, in the four areas of oncology, immuno-oncology, immunology and multiple sclerosis.
David Bates11/09/2015 - 11:00Professor Bates briefly summarised progress made by the recipients of the 2013 and 2014 grants.
Elga de Vries11/17/2015 - 13:31Microglia in MS might have two different phenotypes, according to Dr. de Fries. M1 were pro-inflammatory and neurodestructive and might also be deleterious to neuronal function; M2 were anti-inflammatory and neuro-protective.
Laura Airas11/17/2015 - 13:40In her speech, the award winner Dr. Airas, said that it had been very difficult to find treatments for progressive multiple sclerosis. One reason was that the pathology changes as the disease progresses.
GMSI Award 2015 – Driving microglia metabolism towards remyelination and restoration of brain damage in multiple sclerosis
Claudia Verderio11/17/2015 - 13:53According to Dr. Verderio, the new proposal stemmed from data on the biological activity of vesicles from microglia cells, on the proliferation, differentiation and myelination of oligodendrocyte precursor cells (OPCs).
Gabriele de Luca11/17/2015 - 14:03Dr. de Luca explains in his talk that multiple sclerosis was unsurpassed in its variability and clinical outcomes. One of the greatest determinants of disease and disability was entry into the progressive phase.